Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

Betül Oran, Antonio M. Jimenez, Marcos De Lima, Uday R. Popat, Roland Bassett, Borje S. Andersson, Gautam Borthakur, Qaiser Bashir, Julianne Chen, Stefan O. Ciurea, Elias Jabbour, Jorge Cortes, Partow Kebriaei, Issa F. Khouri, Muzaffar H. Qazilbash, Farhad Ravandi, Gabriela Rondon, Xinyan Lu, Elizabeth J. Shpall, Richard E. Champlin

Research output: Contribution to journalArticle

Abstract

We evaluated the prognostic significance of a modified European LeukemiaNet (ELN) classification for patients with acute myelogenous leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT) while in first complete remission (CR1). We analyzed 464 AML patients with matched related (n= 211, 45.5%), matched unrelated (n= 176, 37.9%), and mismatched donors (n= 77, 16.6%). Patients were classified into 4 modified ELN risk groups (favorable, intermediate-I, intermediate-II, and adverse) separately for 354 patients age < 60 years and 110 patients age ≥ 60 years. In this modified version of ELN classification, patients with normal cytogenetic were classified by FLT3-ITD mutational status: favorable risk if FLT3-ITDwild and intermediate-I if FLT3-ITDmut. The best outcomes occurred in the ELN favorable and intermediate-II groups in younger AML patients and in the favorable and intermediate-I groups in older AML patients. Older AML patients had worse transplant outcomes within each modified ELN risk group except intermediate-I when compared with younger patients; leukemia-free survival at 3 years was 67.8% versus 49.8% in favorable, 53.4% versus 50.7% in intermediate-I, 65.7% versus 20.2% in intermediate-II, and 44.6% versus 23.8% in adverse group younger and older patients, respectively. Among lesion-specific abnormalities, del5q/-5 and abnl(17p) had the worse transplant outcomes, with 3-year leukemia-free survival rates of 18.4% and 20% in younger CR1 patients. In conclusion, the modified ELN prognostic classification developed for chemotherapy outcomes also identifies prognostic groups for HSCT, which is useful for a selection of patients for post-transplant strategies to improve outcomes.

Original languageEnglish (US)
Pages (from-to)1405-1412
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number8
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Acute Myeloid Leukemia
Transplants
Hematopoietic Stem Cell Transplantation
Leukemia
Cytogenetics
Patient Selection
Survival Rate
Tissue Donors

Keywords

  • Allogeneic stem cell transplantation
  • AML
  • European LeukemiaNet
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes : An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. / Oran, Betül; Jimenez, Antonio M.; De Lima, Marcos; Popat, Uday R.; Bassett, Roland; Andersson, Borje S.; Borthakur, Gautam; Bashir, Qaiser; Chen, Julianne; Ciurea, Stefan O.; Jabbour, Elias; Cortes, Jorge; Kebriaei, Partow; Khouri, Issa F.; Qazilbash, Muzaffar H.; Ravandi, Farhad; Rondon, Gabriela; Lu, Xinyan; Shpall, Elizabeth J.; Champlin, Richard E.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 8, 01.08.2015, p. 1405-1412.

Research output: Contribution to journalArticle

Oran, B, Jimenez, AM, De Lima, M, Popat, UR, Bassett, R, Andersson, BS, Borthakur, G, Bashir, Q, Chen, J, Ciurea, SO, Jabbour, E, Cortes, J, Kebriaei, P, Khouri, IF, Qazilbash, MH, Ravandi, F, Rondon, G, Lu, X, Shpall, EJ & Champlin, RE 2015, 'Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 21, no. 8, pp. 1405-1412. https://doi.org/10.1016/j.bbmt.2015.03.023
Oran, Betül ; Jimenez, Antonio M. ; De Lima, Marcos ; Popat, Uday R. ; Bassett, Roland ; Andersson, Borje S. ; Borthakur, Gautam ; Bashir, Qaiser ; Chen, Julianne ; Ciurea, Stefan O. ; Jabbour, Elias ; Cortes, Jorge ; Kebriaei, Partow ; Khouri, Issa F. ; Qazilbash, Muzaffar H. ; Ravandi, Farhad ; Rondon, Gabriela ; Lu, Xinyan ; Shpall, Elizabeth J. ; Champlin, Richard E. / Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes : An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2015 ; Vol. 21, No. 8. pp. 1405-1412.
@article{e4c1883e6dc34bd48919029914091a8e,
title = "Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation",
abstract = "We evaluated the prognostic significance of a modified European LeukemiaNet (ELN) classification for patients with acute myelogenous leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT) while in first complete remission (CR1). We analyzed 464 AML patients with matched related (n= 211, 45.5{\%}), matched unrelated (n= 176, 37.9{\%}), and mismatched donors (n= 77, 16.6{\%}). Patients were classified into 4 modified ELN risk groups (favorable, intermediate-I, intermediate-II, and adverse) separately for 354 patients age < 60 years and 110 patients age ≥ 60 years. In this modified version of ELN classification, patients with normal cytogenetic were classified by FLT3-ITD mutational status: favorable risk if FLT3-ITDwild and intermediate-I if FLT3-ITDmut. The best outcomes occurred in the ELN favorable and intermediate-II groups in younger AML patients and in the favorable and intermediate-I groups in older AML patients. Older AML patients had worse transplant outcomes within each modified ELN risk group except intermediate-I when compared with younger patients; leukemia-free survival at 3 years was 67.8{\%} versus 49.8{\%} in favorable, 53.4{\%} versus 50.7{\%} in intermediate-I, 65.7{\%} versus 20.2{\%} in intermediate-II, and 44.6{\%} versus 23.8{\%} in adverse group younger and older patients, respectively. Among lesion-specific abnormalities, del5q/-5 and abnl(17p) had the worse transplant outcomes, with 3-year leukemia-free survival rates of 18.4{\%} and 20{\%} in younger CR1 patients. In conclusion, the modified ELN prognostic classification developed for chemotherapy outcomes also identifies prognostic groups for HSCT, which is useful for a selection of patients for post-transplant strategies to improve outcomes.",
keywords = "Allogeneic stem cell transplantation, AML, European LeukemiaNet, Prognosis",
author = "Bet{\"u}l Oran and Jimenez, {Antonio M.} and {De Lima}, Marcos and Popat, {Uday R.} and Roland Bassett and Andersson, {Borje S.} and Gautam Borthakur and Qaiser Bashir and Julianne Chen and Ciurea, {Stefan O.} and Elias Jabbour and Jorge Cortes and Partow Kebriaei and Khouri, {Issa F.} and Qazilbash, {Muzaffar H.} and Farhad Ravandi and Gabriela Rondon and Xinyan Lu and Shpall, {Elizabeth J.} and Champlin, {Richard E.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2015.03.023",
language = "English (US)",
volume = "21",
pages = "1405--1412",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes

T2 - An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

AU - Oran, Betül

AU - Jimenez, Antonio M.

AU - De Lima, Marcos

AU - Popat, Uday R.

AU - Bassett, Roland

AU - Andersson, Borje S.

AU - Borthakur, Gautam

AU - Bashir, Qaiser

AU - Chen, Julianne

AU - Ciurea, Stefan O.

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kebriaei, Partow

AU - Khouri, Issa F.

AU - Qazilbash, Muzaffar H.

AU - Ravandi, Farhad

AU - Rondon, Gabriela

AU - Lu, Xinyan

AU - Shpall, Elizabeth J.

AU - Champlin, Richard E.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - We evaluated the prognostic significance of a modified European LeukemiaNet (ELN) classification for patients with acute myelogenous leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT) while in first complete remission (CR1). We analyzed 464 AML patients with matched related (n= 211, 45.5%), matched unrelated (n= 176, 37.9%), and mismatched donors (n= 77, 16.6%). Patients were classified into 4 modified ELN risk groups (favorable, intermediate-I, intermediate-II, and adverse) separately for 354 patients age < 60 years and 110 patients age ≥ 60 years. In this modified version of ELN classification, patients with normal cytogenetic were classified by FLT3-ITD mutational status: favorable risk if FLT3-ITDwild and intermediate-I if FLT3-ITDmut. The best outcomes occurred in the ELN favorable and intermediate-II groups in younger AML patients and in the favorable and intermediate-I groups in older AML patients. Older AML patients had worse transplant outcomes within each modified ELN risk group except intermediate-I when compared with younger patients; leukemia-free survival at 3 years was 67.8% versus 49.8% in favorable, 53.4% versus 50.7% in intermediate-I, 65.7% versus 20.2% in intermediate-II, and 44.6% versus 23.8% in adverse group younger and older patients, respectively. Among lesion-specific abnormalities, del5q/-5 and abnl(17p) had the worse transplant outcomes, with 3-year leukemia-free survival rates of 18.4% and 20% in younger CR1 patients. In conclusion, the modified ELN prognostic classification developed for chemotherapy outcomes also identifies prognostic groups for HSCT, which is useful for a selection of patients for post-transplant strategies to improve outcomes.

AB - We evaluated the prognostic significance of a modified European LeukemiaNet (ELN) classification for patients with acute myelogenous leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT) while in first complete remission (CR1). We analyzed 464 AML patients with matched related (n= 211, 45.5%), matched unrelated (n= 176, 37.9%), and mismatched donors (n= 77, 16.6%). Patients were classified into 4 modified ELN risk groups (favorable, intermediate-I, intermediate-II, and adverse) separately for 354 patients age < 60 years and 110 patients age ≥ 60 years. In this modified version of ELN classification, patients with normal cytogenetic were classified by FLT3-ITD mutational status: favorable risk if FLT3-ITDwild and intermediate-I if FLT3-ITDmut. The best outcomes occurred in the ELN favorable and intermediate-II groups in younger AML patients and in the favorable and intermediate-I groups in older AML patients. Older AML patients had worse transplant outcomes within each modified ELN risk group except intermediate-I when compared with younger patients; leukemia-free survival at 3 years was 67.8% versus 49.8% in favorable, 53.4% versus 50.7% in intermediate-I, 65.7% versus 20.2% in intermediate-II, and 44.6% versus 23.8% in adverse group younger and older patients, respectively. Among lesion-specific abnormalities, del5q/-5 and abnl(17p) had the worse transplant outcomes, with 3-year leukemia-free survival rates of 18.4% and 20% in younger CR1 patients. In conclusion, the modified ELN prognostic classification developed for chemotherapy outcomes also identifies prognostic groups for HSCT, which is useful for a selection of patients for post-transplant strategies to improve outcomes.

KW - Allogeneic stem cell transplantation

KW - AML

KW - European LeukemiaNet

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84937730288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937730288&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.03.023

DO - 10.1016/j.bbmt.2015.03.023

M3 - Article

C2 - 25840338

AN - SCOPUS:84937730288

VL - 21

SP - 1405

EP - 1412

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -